dapiglutide vs PG-102

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GLP-2 receptor (dual) · full Obesity pipeline

dapiglutide

Developed by Zealand Pharma

Phase 2 in Obesitypeptide
Partial signal

NCT05788601 · Phase 2 · active, not recruiting

This was a randomized, double-blind, placebo-controlled trial with an appropriate hard endpoint (percentage body weight change), but the study enrolled only 54 participants and the primary comparison for the higher dose narrowly missed statistical significance versus placebo. Because the well-designed trial's key result was not a statistically significant win, it counts as solid but inconclusive evidence rather than proof of benefit.

Reported efficacy

Percentage change in body weight (kg) (From week 0 (baseline) to week 12 (end of treatment)): NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. (missed)

Result source: NCT05788601

PG-102

Developed by ProGen

Phase 2 in Obesityfusion protein
Partial signal

NCT06309667 · Phase 1 · completed

Every dose cohort in this study randomized participants to PG-102 or matching placebo under double-blind conditions, a controlled design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The source does not cite the trial's registry number and reports the sponsor's disclosure second-hand; identity rests on this being the sponsor's only phase 1 study enrolling obese participants.

Reported efficacy

Number of participants with treatment-emergent adverse events (TEAEs) for Part A (Baseline to Day 29); Number of participants with treatment-emergent adverse events (TEAEs) for Part B (Baseline to Day 57); Number of participants with Serious adverse events (SAEs) as assessed by CTCAE v5.0 for Part A (Baseline to Day 29); Number of participants with Serious adverse events (SAEs) as assessed by CTCAE v5.0 for Part B (Baseline to Day 57); Number of participants with clinically significant abnormalities in vital signs for Part A (Baseline to Day 29); Number of participants with clinically significant abnormalities in vital signs for Part B (Baseline to Day 57); Number of participants with clinically significant abnormalities in 12-lead ECGs for Part A (Baseline to Day 29); Number of participants with clinically significant abnormalities in 12-lead ECGs for Part B (Baseline to Day 57): In a phase 1 study in obese patients, PG-102 achieved a -4.84 percent weight reduction in five weeks.

Result source: NCT06309667

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdapiglutidePG-102
Body weight, % change—Not reported—Not reported
Weight loss of 5% or more—Not reported—Not reported
Weight loss of 10% or more—Not reported—Not reported
Waist circumference, change (cm)—Not reported—Not reported

Body weight, % change

dapiglutide
—Not reported
PG-102
—Not reported

Weight loss of 5% or more

dapiglutide
—Not reported
PG-102
—Not reported

Weight loss of 10% or more

dapiglutide
—Not reported
PG-102
—Not reported

Waist circumference, change (cm)

dapiglutide
—Not reported
PG-102
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

PG-102: no structured comparison results are available for Obesity.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

dapiglutide
NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. NCT05788601 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dapiglutide's landscape · PG-102's landscape